For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...
Amazon S3 on MSN
WHO supports weight loss drugs for tackling obesity crisis
Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...
GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...
Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its ...
A session at the AHA Scientific Sessions 2025 focused on the latest groundbreaking trails in cardiometabolic therapies.
News Medical on MSN
Diabetes drugs may help older adults slow frailty, suggests study
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. MetaVia ( (MTVA) ) has provided an announcement.
Australia’s TGA has issued updated safety warnings for GLP-1 drugs like Ozempic and Mounjaro, highlighting mental-health ...
The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an ...
The guideline specifies that drugs alone are not enough and emphasizes the need for behavioral and lifestyle interventions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback